Inmune Bio, Inc. SEC filings INMB
Inmune Bio, Inc. has 601 filings in SEC EDGAR's recent list, going back to Jul 13, 2017. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Oct 29, 2026 | — |
| 424B5 | Prospectus supplement | Dec 19, 2025 | — |
| 424B5 | Prospectus supplement | Jun 30, 2025 | — |
| S-8 | Employee stock plan registration | Jun 16, 2025 | — |
| S-8 | Employee stock plan registration | Jun 16, 2025 | — |
| 424B5 | Prospectus supplement | Mar 7, 2025 | — |
| 424B5 | Prospectus supplement | Sep 16, 2024 | — |
| 424B5 | Prospectus supplement | Aug 9, 2024 | — |
| S-3/A | Amendment no. 1 to form s-3 | Aug 2, 2024 | — |
| S-3 | Shelf registration | May 1, 2024 | — |
| 424B5 | Prospectus supplement | Apr 26, 2024 | — |
| 424B5 | Prospectus supplement | Apr 22, 2024 | — |
| 424B5 | Prospectus supplement | Aug 16, 2023 | — |
| S-8 | Employee stock plan registration | Jun 20, 2023 | — |
| S-8 POS | Post-effective amendment no. 1 to form s-8 | Jun 20, 2023 | — |
| 424B3 | Prospectus | Sep 21, 2021 | — |
| S-3 | Shelf registration | Sep 7, 2021 | — |
| 424B5 | Prospectus supplement | Jul 15, 2021 | — |
| S-3 | Shelf registration | Apr 9, 2021 | — |
| S-8 | Employee stock plan registration | Mar 22, 2021 | — |
| S-3 | Shelf registration | Mar 12, 2021 | — |
| 424B5 | Prospectus supplement | Mar 11, 2021 | — |
| 424B5 | Prospectus supplement | Aug 19, 2020 | — |
| 424B5 | Prospectus supplement | Jul 16, 2020 | — |
| 424B5 | Prospectus supplement | Jul 15, 2020 | — |
| 424B3 | Prospectus | Apr 24, 2020 | — |
| 424B5 | Prospectus supplement | Apr 17, 2020 | — |
| POS AM | Post-effective amendment to form s-1 | Apr 14, 2020 | — |
| S-3 | Shelf registration | Mar 24, 2020 | — |
| 424B3 | Prospectus | Jul 26, 2019 | — |
| S-1 | Registration statement | Jul 18, 2019 | — |
| 424B3 | Prospectus | Jul 3, 2019 | — |
| S-1 | Registration statement | Jun 21, 2019 | — |
| FWP | Free writing prospectus | Jan 24, 2019 | — |
| 424B3 | Prospectus | Dec 21, 2018 | — |
| S-1/A | Amended registration statement | Nov 20, 2018 | — |
| FWP | Free writing prospectus | Nov 1, 2018 | — |
| S-1/A | Amended registration statement | Oct 29, 2018 | — |
| FWP | Free writing prospectus | Oct 5, 2018 | — |
| S-1/A | Amended registration statement | Sep 26, 2018 | — |
| FWP | Free writing prospectus | Sep 6, 2018 | — |
| S-1 | Registration statement | Aug 30, 2018 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Boca Raton, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1711754
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.